Followers | 25 |
Posts | 2502 |
Boards Moderated | 0 |
Alias Born | 03/18/2013 |

Wednesday, March 12, 2025 11:25:15 PM
Recent AMRN News
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 03/12/2025 11:46:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2025 11:05:07 AM
- Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program • GlobeNewswire Inc. • 03/12/2025 11:01:00 AM
- Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action • GlobeNewswire Inc. • 03/12/2025 11:00:00 AM
- Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering • GlobeNewswire Inc. • 02/27/2025 02:00:00 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Austria • GlobeNewswire Inc. • 02/25/2025 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 • GlobeNewswire Inc. • 02/19/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 09:15:07 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Italy • GlobeNewswire Inc. • 12/16/2024 12:00:00 PM
- Amarin Appoints Peter Fishman Chief Financial Officer • GlobeNewswire Inc. • 12/13/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 09:49:38 PM
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making • SIGY • Mar 12, 2025 9:41 AM
$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market • NRXS • Mar 11, 2025 10:30 AM
UC Asset Acquired $3M Cannabis Property via Non-Cash Deal • UCASU • Mar 11, 2025 9:53 AM
1606 Corp. Signs LOI to Be Acquired by Private Group Seeking to Enter the Public Markets and Utilize AI Technologies for Potential Uplisting • CBDW • Mar 11, 2025 8:30 AM
Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 • ELAB • Mar 10, 2025 9:05 AM
North Bay Resources Announces Assays up to 5.69% Copper, 1 Opt. Silver, and 0.22% Vanadium at Copper Island Project, British Columbia • NBRI • Mar 10, 2025 9:00 AM